Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Expanded Cohort for MCRC Using Bevacizumab + Everolimus (BEV/EV)
This study is currently recruiting participants.
Study NCT00597506 Information provided by Duke University
First Received: December 26, 2007 Last Updated: March 15, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Colorectal Adenocarcinoma
Additional conditions recognized in this trial
Adenocarcinoma
Colorectal Neoplasms
More general conditions related to this trial
Carcinoma
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Rectal Diseases
Interventions listed in this trial
bevacizumab + everolimus
Additional drug interventions recognized in this trial
Bevacizumab
Everolimus
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Duke University
Novartis Pharmaceuticals
Genentech
Back to top of Main Content
